骨质疏松症治疗史与接受第二剂唑来膦酸的关系
研究分析了2006至2021年加拿大安大略省启动公立资助唑来膦酸治疗的3308例骨质疏松患者,81%为女性,中位年龄77岁;31%接受了第二次输注。有口服双膦酸盐史者占49%,无治疗史者占37%,地舒单抗史者占11%,其他药物史者占3%。有口服双膦酸盐史者接受第二剂的可能性是无治疗史者的1.5倍(HR 1.50,95%CI 1.31-1.71)。
要点
- 多数启动唑来膦酸治疗的患者已有骨质疏松药物治疗史,与关键临床试验中未经治疗的患者不同。
- 有口服双膦酸盐史者接受第二剂唑来膦酸的可能性是无治疗史者的1.5倍(HR 1.50,95%CI 1.31-1.71)。
- 仅31%的患者接受了第二剂唑来膦酸,需进一步研究治疗决策和患者信念。
核心结论
- 与关键临床试验中的患者不同,大多数接受唑来膦酸的患者既往已有骨质疏松药物治疗;有口服双膦酸盐使用史者接受第二剂的比例更高,围绕接受第二剂唑来膦酸的治疗决策和患者信念应进一步研究。
研究设计与样本
- 使用加拿大安大略省医疗行政数据,识别2006年10月至2021年10月启动公立资助唑来膦酸治疗的老年患者,随访至2022年10月;根据5年骨质疏松治疗回顾史分为无史、地舒单抗、口服双膦酸盐和其他药物四组,采用Cox比例风险模型比较接受第二剂唑来膦酸的情况。
主要发现
- 共识别3308例启动唑来膦酸治疗的患者,中位年龄77岁,81%为女性,31%接受了第二次输注。
- 49%有口服双膦酸盐史,37%无治疗史,11%有地舒单抗史,3%有其他药物史。
- 有口服双膦酸盐史者接受第二剂的可能性是无治疗史者的1.5倍(HR 1.50,95%CI 1.31-1.71)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: We examined characteristics of patients in Ontario, Canada, initiating publicly funded zoledronic acid for osteoporosis from 2006 to 2021. Most patients had prior osteoporosis treatments, with those previously using oral bisphosphonates more likely to receive a second dose. Understanding treatment decisions and patient beliefs is key for future research. PURPOSE: Zoledronic acid is a once-yearly intravenous bisphosphonate and is considered a second-line osteoporosis therapy in Ontario, Canada. This regimen was approved using evidence from clinical trials of treatment-naïve patients. However, many patients initiating zoledronic acid have used other osteoporosis medications prior, which may influence the frequency of dosing. We describe the characteristics of patients initiating zoledronic acid and identify if previous osteoporosis pharmacotherapy impacts the receipt of a second dose. METHODS: Healthcare administrative data in Ontario were used to identify older patients initiating publicly funded zoledronic acid from 10/2006 to 10/2021 and followed until 10/2022. Patients were categorized based on 5-year osteoporosis treatment look back history in mutually exclusive groups: (1) no history, (2) denosumab, (3) oral bisphosphonates, and (4) other osteoporosis medications. Cox proportional hazards models were used to compare receipt of a second zoledronic acid infusion between patients in treatment history groups. RESULTS: We identified 3308 patients initiating zoledronic acid; median age = 77, 81% female, 31% received a second infusion of zoledronic acid. Half (49%) had a history of oral bisphosphonates, 37% no history, 11% denosumab, and 3% other medications. Overall, patients having history of oral bisphosphonates were 1.5 times more likely to receive a second dose relative to no history (HR, 95%CI: 1.50 [1.31-1.71]). CONCLUSION: In contrast to patients in pivotal trials, most patients receiving zoledronic acid had prior osteoporosis pharmacotherapy. Patients with prior oral bisphosphonate use had higher rates of receiving a second dose. Better understanding of treatment decisions and patient beliefs around receiving a second infusion of zoledronic acid should be further investigated.
引用
- Konstantelos N, Kim S, Cheung AM, et al. The relationship between osteoporosis treatment history and receipt of a second zoledronic acid dose. Osteoporos Int. 2025. PMID: 40906172. doi:10.1007/s00198-025-07672-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。